Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

... and Gets FDA Backing for Avandia

August 6, 2007 | A version of this story appeared in Volume 85, Issue 32

By a vote of 22-1, an FDA advisory panel voted last week to keep GlaxoSmithKline's diabetes treatment Avandia on the U.S. market, despite safety concerns. FDA issued a safety alert regarding Avandia in May, citing data from clinical trials that indicate a "potentially significant increase" in the risk of heart attack for patients. However, FDA also cited results from other tests contradicting this data. Avandia, with worldwide sales of about $3 billion, two-thirds of which are in the U.S., is GSK's second largest selling drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.